The recombinant globular head domain of the measles virus hemagglutinin protein as a subunit vaccine against measles
Autor: | Liubov M. Lobanova, Alexander N. Zakhartchouk, George Mutwiri, James M. Rini, Nelson F. Eng, Malathy Satkunarajah |
---|---|
Rok vydání: | 2012 |
Předmět: |
Protein subunit
Measles Vaccine Hemagglutinins Viral Hemagglutinin (influenza) Antibodies Viral Cell Line law.invention Measles virus Interferon-gamma Mice 03 medical and health sciences Th2 Cells 0302 clinical medicine Immune system law Animals Humans 030212 general & internal medicine 030304 developmental biology Vaccines Synthetic 0303 health sciences Attenuated vaccine General Veterinary General Immunology and Microbiology biology Immunogenicity Public Health Environmental and Occupational Health Th1 Cells biology.organism_classification Antibodies Neutralizing Virology Recombinant Proteins 3. Good health Infectious Diseases Vaccines Subunit Leukocytes Mononuclear biology.protein Recombinant DNA Molecular Medicine Interleukin-5 Antibody Measles |
Zdroj: | Vaccine. 30:3061-3067 |
ISSN: | 0264-410X |
Popis: | Despite the availability of live attenuated measles virus (MV) vaccines, a large number of measles-associated deaths occur among infants in developing countries. The development of a measles subunit vaccine may circumvent the limitations associated with the current live attenuated vaccines and eventually contribute to global measles eradication. Therefore, the goal of this study was to test the feasibility of producing the recombinant globular head domain of the MV hemagglutinin (H) protein by stably transfected human cells and to examine the ability of this recombinant protein to elicit MV-specific immune responses. The recombinant protein was purified from the culture supernatant of stably transfected HEK293T cells secreting a tagged version of the protein. Two subcutaneous immunizations with the purified recombinant protein alone resulted in the production of MV-specific serum IgG and neutralizing antibodies in mice. Formulation of the protein with adjuvants (polyphosphazene or alum) further enhanced the humoral immune response and in addition resulted in the induction of cell-mediated immunity as measured by the production of MV H-specific interferon gamma (IFN-γ) and interleukin 5 (IL-5) by in vitro re-stimulated splenocytes. Furthermore, the inclusion of polyphosphazene into the vaccine formulation induced a mixed Th1/Th2-type immune response. In addition, the purified recombinant protein retained its immunogenicity even after storage at 37 °C for 2 weeks. |
Databáze: | OpenAIRE |
Externí odkaz: |